Baraclude

1.

NAME OF THE MEDICINAL PRODUCT

Baraclude 0.5 mg film-coated tablets

2.

QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 0.5 mg entecavir (as monohydrate).

Excipients: each tablet contains 120.5 mg lactose.

For a full list of excipients, see section 6.1.

3.

PHARMACEUTICAL FORM

Film-coated tablet (tablet)

White to off-white and triangular-shaped tablet with “BMS” debossed on one side and “1611” on the

other.

4.

CLINICAL PARTICULARS

4.1 Therapeutic indications

Baraclude is indicated for the treatment of chronic hepatitis B virus (HBV) infection (see section 5.1)

in adults with:



compensated liver disease and evidence of active viral replication, persistently elevated serum

alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or

fibrosis.



decompensated liver disease (see section 4.4)

For both compensated and decompensated liver disease, this indication is based on clinical trial data in

nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to

patients with lamivudine-refractory hepatitis B, see sections 4.4 and 5.1.

4.2 Posology and method of administration

Therapy should be initiated by a physician experienced in the management of chronic hepatitis B

infection.

Baraclude should be taken orally, once-daily.

Compensated liver disease

Nucleoside naïve patients: the recommended dose is 0.5 mg once daily, with or without food.

Lamivudine-refractory patients (i.e. with evidence of viraemia while on lamivudine or the presence of

lamivudine resistance [LVDr] mutations) (see sections 4.4 and 5.1): the recommended dose is 1 mg

once daily, which must be taken on an empty stomach (more than 2 hours before or more than 2 hours

after a meal) (see section 5.2).

Decompensated liver disease

The recommended dose for patients with decompensated liver disease is 1 mg once daily, which must

be taken on an empty stomach (more than 2 hours before or more than 2 hours after a meal) (see

2

section 5.2). For patients with lamivudine-refractory hepatitis B, see sections 4.4 and 5.1.

Duration of therapy

The optimal duration of treatment is unknown. Treatment discontinuation may be considered as

follows:

 In HBeAg positive patients, treatment should be administered at least until HBe seroconversion

(HBeAg loss and HBV DNA loss with anti-HBe detection on two consecutive serum samples at

least 3-6 months apart) or until HBs seroconversion or there is loss of efficacy (see section 4.4).

 In HBeAg negative patients, treatment should be administered at least until HBs seroconversion

or there is evidence of loss of efficacy. With prolonged treatment for more than 2 years, regular

reassessment is recommended to confirm that continuing the selected therapy remains

appropriate for the patient.

In patients with decompensated liver disease or cirrhosis, treatment cessation is not recommended.

Elderly: no dosage adjustment based on age is required. The dose should be adjusted according to the

patient’s renal function (see dosage recommendations in renal impairment and section 5.2).

Gender and race: no dosage adjustment based on gender or race is required.

Renal impairment: the clearance of entecavir decreases with decreasing creatinine clearance (see

section 5.2). Dose adjustment is recommended for patients with creatinine clearance < 50 ml/min,

including those on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD). A reduction

of the daily dose using Baraclude oral solution, as detailed in the table, is recommended. As an

alternative, in case the oral solution is not available, the dose can be adjusted by increasing the dosage

interval, also shown in the table. The proposed dose modifications are based on extrapolation of

limited data, and their safety and effectiveness have not been clinically evaluated. Therefore,

virological response should be closely monitored.

Baraclude dosage*

Creatinine clearance

(ml/min )

Nucleoside naïve patients

Lamivudine-refractory or

decompensated liver disease

≥ 50

0.5 mg once daily

1 mg once daily

30 - 49

0.25 mg once daily*

OR

0.5 mg every 48 hours

0.5 mg once daily

10 - 29

0.15 mg once daily*

OR

0.5 mg every 72 hours

0.3 mg once daily*

OR

0.5 mg every 48 hours

< 10

Haemodialysis or

CAPD**

0.05 mg once daily*

OR

0.5 mg every 5-7 days

0.1 mg once daily*

OR

0.5 mg every 72 hours

* for doses < 0.5 mg Baraclude oral solution is recommended.

** on haemodialysis days, administer entecavir after haemodialysis.

Hepatic impairment: no dose adjustment is required in patients with hepatic impairment.

Paediatric population: the safety and efficacy of Baraclude in children below 18 years of age have not

yet been established. No data are available.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients.

3

4.4 Special warnings and precautions for use

Renal impairment: dosage adjustment is recommended for patients with renal impairment (see

section 4.2). The proposed dose modifications are based on extrapolation of limited data, and their

safety and effectiveness have not been clinically evaluated. Therefore, virological response should be

closely monitored.

Exacerbations of hepatitis: spontaneous exacerbations in chronic hepatitis B are relatively common

and are characterised by transient increases in serum ALT. After initiating antiviral therapy, serum

ALT may increase in some patients as serum HBV DNA levels decline (see section 4.8). Among

entecavir-treated patients on-treatment exacerbations had a median time of onset of 4-5 weeks. In

patients with compensated liver disease, these increases in serum ALT are generally not accompanied

by an increase in serum bilirubin concentrations or hepatic decompensation. Patients with advanced

liver disease or cirrhosis may be at a higher risk for hepatic decompensation following hepatitis

exacerbation, and therefore should be monitored closely during therapy.

Acute exacerbation of hepatitis has also been reported in patients who have discontinued hepatitis B

therapy (see section 4.2). Post-treatment exacerbations are usually associated with rising HBV DNA,

and the majority appears to be self-limited. However, severe exacerbations, including fatalities, have

been reported.

Among entecavir-treated nucleoside naive patients, post-treatment exacerbations had a median time to

onset of 23-24 weeks, and most were reported in HBeAg negative patients (see section 4.8). Hepatic

function should be monitored at repeated intervals with both clinical and laboratory follow-up for at

least 6 months after discontinuation of hepatitis B therapy. If appropriate, resumption of hepatitis B

therapy may be warranted.

Patients with decompensated liver disease: a higher rate of serious hepatic adverse events (regardless

of causality) has been observed in patients with decompensated liver disease, in particular in those

with Child-Turcotte-Pugh (CTP) class C disease, compared with rates in patients with compensated

liver function. Also, patients with decompensated liver disease may be at higher risk for lactic acidosis

and for specific renal adverse events such as hepatorenal syndrome. Therefore, clinical and laboratory

parameters should be closely monitored in this patient population (see also sections 4.8 and 5.1).

Lactic acidosis and severe hepatomegaly with steatosis: occurrences of lactic acidosis (in the absence

of hypoxaemia), sometimes fatal, usually associated with severe hepatomegaly and hepatic steatosis,

have been reported with the use of nucleoside analogues. As entecavir is a nucleoside analogue, this

risk cannot be excluded. Treatment with nucleoside analogues should be discontinued when rapidly

elevating aminotransferase levels, progressive hepatomegaly or metabolic/lactic acidosis of unknown

aetiology occur. Benign digestive symptoms, such as nausea, vomiting and abdominal pain, might be

indicative of lactic acidosis development. Severe cases, sometimes with fatal outcome, were associated

with pancreatitis, liver failure/hepatic steatosis, renal failure and higher levels of serum lactate.

Caution should be exercised when prescribing nucleoside analogues to any patient (particularly obese

women) with hepatomegaly, hepatitis or other known risk factors for liver disease. These patients

should be followed closely.

To differentiate between elevations in aminotransferases due to response to treatment and increases

potentially related to lactic acidosis, physicians should ensure that changes in ALT are associated with

improvements in other laboratory markers of chronic hepatitis B.

Resistance and specific precaution for lamivudine-refractory patients: mutations in the HBV

polymerase that encode lamivudine-resistance substitutions may lead to the subsequent emergence of

secondary substitutions, including those associated with entecavir associated resistance (ETVr). In a

small percentage of lamivudine-refractory patients, ETVr substitutions at residues rtT184, rtS202 or

rtM250 were present at baseline. Patients with lamivudine-resistant HBV are at higher risk of

developing subsequent entecavir resistance than patients without lamivudine resistance. The

cumulative probability of emerging genotypic entecavir resistance after 1, 2, 3, 4 and 5 years treatment

4

in the lamivudine-refractory studies was 6%, 15%, 36%, 47% and 51%, respectively. Virological

response should be frequently monitored in the lamivudine-refractory population and appropriate

resistance testing should be performed. In patients with a suboptimal virological response after 24

weeks of treatment with entecavir, a modification of treatment should be considered (see sections 4.5

and 5.1).

Pre-existing lamivudine-resistant HBV is associated with an increased risk for subsequent entecavir

resistance regardless of the degree of liver disease; in patients with decompensated liver disease,

virologic breakthrough may be associated with serious clinical complications of the underlying liver

disease. Therefore, in patients with both decompensated liver disease and lamivudine-resistant HBV,

combination use of entecavir plus a second antiviral agent (which does not share cross-resistance with

either lamivudine or entecavir) should be considered in preference to entecavir monotherapy.

Liver transplant recipients: there are limited data on efficacy and safety of entecavir in liver transplant

recipients. Renal function should be carefully evaluated before and during entecavir therapy in liver

transplant recipients receiving cyclosporine or tacrolimus (see section 5.2).

Co-infection with hepatitis C or D: there are no data on the efficacy of entecavir in patients co-infected

with hepatitis C or D virus.

Human immunodeficiency virus (HIV)/HBV co-infected patients not receiving concomitant

antiretroviral therapy: entecavir has not been evaluated in HIV/HBV co-infected patients not

concurrently receiving effective HIV treatment. Emergence of HIV resistance has been observed when

entecavir was used to treat chronic hepatitis B infection in patients with HIV infection not receiving

highly active antiretroviral therapy (HAART) (see section 5.1). Therefore, therapy with entecavir

should not be used for HIV/HBV co-infected patients who are not receiving HAART. Entecavir has

not been studied as a treatment for HIV infection and is not recommended for this use.

HIV/HBV co-infected patients receiving concomitant antiretroviral therapy : entecavir has been studied

in 68 adults with HIV/HBV co-infection receiving a lamivudine-containing HAART regimen (see

section 5.1). No data are available on the efficacy of entecavir in HBeAg-negative patients co-infected

with HIV. There are limited data on patients co-infected with HIV who have low CD4 cell counts

(< 200 cells/mm 3 ).

General: patients should be advised that therapy with entecavir has not been proven to reduce the risk

of transmission of HBV and therefore appropriate precautions should still be taken.

Lactose: this medicinal product contains 120.5 mg of lactose in each 0.5 mg daily dose.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or

glucose-galactose malabsorption should not take this medicine. A lactose-free Baraclude oral solution

is available for these individuals.

4.5 Interaction with other medicinal products and other forms of interaction

Since entecavir is predominantly eliminated by the kidney (see section 5.2), coadministration with

medicinal products that reduce renal function or compete for active tubular secretion may increase

serum concentrations of either medicinal product. Apart from lamivudine, adefovir dipivoxil and

tenofovir disoproxil fumarate, the effects of coadministration of entecavir with medicinal products that

are excreted renally or affect renal function have not been evaluated. Patients should be monitored

closely for adverse reactions when entecavir is coadministered with such medicinal products.

No pharmacokinetic interactions between entecavir and lamivudine, adefovir or tenofovir were

observed.

Entecavir is not a substrate, an inducer or an inhibitor of cytochrome P450 (CYP450) enzymes (see

section 5.2). Therefore CYP450 mediated drug interactions are unlikely to occur with entecavir.

5

4.6 Fertility, pregnancy and lactation

Women of childbearing potential: given that the potential risks to the developing foetus are unknown,

women of childbearing potential should use effective contraception.

Pregnancy: there are no adequate data from the use of entecavir in pregnant women. Studies in

animals have shown reproductive toxicity at high doses (see section 5.3). The potential risk for

humans is unknown. Baraclude should not be used during pregnancy unless clearly necessary. There

are no data on the effect of entecavir on transmission of HBV from mother to newborn infant.

Therefore, appropriate interventions should be used to prevent neonatal acquisition of HBV.

Breastfeeding: it is unknown whether entecavir is excreted in human milk. Available toxicological

data in animals have shown excretion of entecavir in milk (for details see section 5.3). A risk to the

infants cannot be excluded. Breastfeeding should be discontinued during treatment with Baraclude.

Fertility: toxicology studies in animals administered entecavir have shown no evidence of impaired

fertility (see section 5.3).

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. No effect on

such activities is expected based on the pharmacodynamic profile of entecavir. Dizziness, fatigue and

somnolence are common side effects which may impair the ability to drive and use machines.

4.8 Undesirable effects

a. Summary of the safety profile

In clinical studies in patients with compensated liver disease, the most common adverse reactions of

any severity with at least a possible relation to entecavir were headache (9%), fatigue (6%), dizziness

(4%) and nausea (3%). Exacerbations of hepatitis during and after discontinuation of entecavir therapy

have also been reported (see section 4.4 and c. Description of selected adverse reactions ).

b. Tabulated list of adverse reactions

Assessment of adverse reactions is based on experience from postmarketing surveillance and four

clinical studies in which 1,720 patients with chronic hepatitis B infection and compensated liver

disease received double-blind treatment with entecavir (n = 862) or lamivudine (n = 858) for up to

107 weeks (see section 5.1). In these studies, the safety profiles, including laboratory abnormalities,

were comparable for entecavir 0.5 mg daily (679 nucleoside-naive HBeAg positive or negative

patients treated for a median of 53 weeks), entecavir 1 mg daily (183 lamivudine-refractory patients

treated for a median of 69 weeks), and lamivudine.

Adverse reactions considered at least possibly related to treatment with entecavir are listed by body

system organ class. Frequency is defined as very common ( 1/10); common ( 1/100 to < 1/10);

uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000). Within each frequency grouping,

undesirable effects are presented in order of decreasing seriousness.

6

Immune system disorders:

rare: anaphylactoid reaction

Psychiatric disorders:

common: insomnia

Nervous system disorders:

common: headache, dizziness, somnolence

Gastrointestinal disorders:

common: vomiting, diarrhoea, nausea, dyspepsia

Hepatobiliary disorders

common: increased transaminases

Skin and subcutaneous tissue disorders:

uncommon: rash, alopecia

General disorders and administration site

conditions:

common: fatigue

Cases of lactic acidosis have been reported, often in association with hepatic decompensation, other

serious medical conditions or drug exposures (see section 4.4).

Treatment beyond 48 weeks: continued treatment with entecavir for a median duration of 96 weeks did

not reveal any new safety signals.

c. Description of selected adverse reactions

Laboratory test abnormalities : In clinical studies with nucleoside-naive patients, 5% had ALT

elevations > 3 times baseline, and < 1% had ALT elevations > 2 times baseline together with total

bilirubin > 2 times upper limit of normal (ULN) and > 2 times baseline. Albumin levels < 2.5 g/dl

occurred in < 1% of patients, amylase levels > 3 times baseline in 2%, lipase levels > 3 times baseline

in 11% and platelets < 50,000/mm 3 in < 1%.

In clinical studies with lamivudine-refractory patients, 4% had ALT elevations > 3 times baseline, and

< 1% had ALT elevations > 2 times baseline together with total bilirubin > 2 times ULN and > 2 times

baseline. Amylase levels > 3 times baseline occurred in 2% of patients, lipase levels > 3 times baseline

in 18% and platelets < 50,000/mm 3 in < 1%.

Exacerbations during treatment: in studies with nucleoside naive patients, on treatment ALT elevations

> 10 times ULN and > 2 times baseline occurred in 2% of entecavir treated patients vs 4% of

lamivudine treated patients. In studies with lamivudine-refractory patients, on treatment ALT

elevations > 10 times ULN and > 2 times baseline occurred in 2% of entecavir treated patients vs 11%

of lamivudine treated patients. Among entecavir-treated patients, on-treatment ALT elevations had a

median time to onset of 4-5 weeks, generally resolved with continued treatment, and, in a majority of

cases, were associated with a ≥ 2 log 10 /ml reduction in viral load that preceded or coincided with the

ALT elevation. Periodic monitoring of hepatic function is recommended during treatment.

Exacerbations after discontinuation of treatment: acute exacerbations of hepatitis have been reported

in patients who have discontinued anti-hepatitis B virus therapy, including therapy with entecavir (see

section 4.4). In studies in nucleoside-naive patients, 6% of entecavir-treated patients and 10% of

lamivudine-treated patients experienced ALT elevations (> 10 times ULN and > 2 times reference

[minimum of baseline or last end-of-dosing measurement]) during post-treatment follow-up. Among

entecavir-treated nucleoside-naive patients, ALT elevations had a median time to onset of

23-24 weeks, and 86% (24/28) of ALT elevations occurred in HBeAg negative patients. In studies in

lamivudine-refractory patients, with only limited numbers of patients being followed up, 11% of

entecavir-treated patients and no lamivudine-treated patients developed ALT elevations during post-

treatment follow-up.

In the clinical trials entecavir treatment was discontinued if patients achieved a prespecified response.

If treatment is discontinued without regard to treatment response, the rate of post-treatment ALT flares

could be higher .

7

d. Other special populations

Experience in patients with decompensated liver disease: the safety profile of entecavir in patients

with decompensated liver disease was assessed in a randomized open-label comparative study in

which patients received treatment with entecavir 1 mg/day (n = 102) or adefovir dipivoxil 10 mg/day

(n = 89) (study 048). Relative to the adverse reactions noted in section b. Tabulated list of adverse

reactions , one additional adverse reaction [decrease in blood bicarbonate (2%)] was observed in

entecavir-treated patients through week 48. The on-study cumulative death rate was 23% (23/102), and

causes of death were generally liver-related, as expected in this population. The on-study cumulative

rate of hepatocellular carcinoma (HCC) was 12% (12/102). Serious adverse events were generally

liver-related, with an on-study cumulative frequency of 69%. Patients with high baseline CTP score

were at higher risk of developing serious adverse events (see section 4.4).

Laboratory test abnormalities: through week 48 among entecavir-treated patients with decompensated

liver disease, none had ALT elevations both > 10 times ULN and > 2 times baseline, and 1% of

patients had ALT elevations > 2 times baseline together with total bilirubin > 2 times ULN and > 2

times baseline. Albumin levels < 2.5 g/dl occurred in 30% of patients, lipase levels > 3 times baseline

in 10% and platelets < 50,000/mm 3 in 20%.

Experience in patients co-infected with HIV: the safety profile of entecavir in a limited number of

HIV/HBV co-infected patients on lamivudine-containing HAART (highly active antiretroviral

therapy) regimens was similar to the safety profile in monoinfected HBV patients (see section 4.4).

Gender/age: there was no apparent difference in the safety profile of entecavir with respect to gender

( 25% women in the clinical trials) or age ( 5% of patients > 65 years of age).

4.9 Overdose

There is limited experience of entecavir overdose reported in patients. Healthy subjects who received

up to 20 mg/day for up to 14 days, and single doses up to 40 mg had no unexpected adverse reactions.

If overdose occurs, the patient must be monitored for evidence of toxicity and given standard

supportive treatment as necessary.

5.

PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: nucleoside and nucleotide reverse transcriptase inhibitors

ATC code: J05AF10

Mechanism of action: entecavir, a guanosine nucleoside analogue with activity against HBV

polymerase, is efficiently phosphorylated to the active triphosphate (TP) form, which has an

intracellular half-life of 15 hours. By competing with the natural substrate deoxyguanosine TP,

entecavir-TP functionally inhibits the 3 activities of the viral polymerase: (1) priming of the HBV

polymerase, (2) reverse transcription of the negative strand DNA from the pregenomic messenger

RNA, and (3) synthesis of the positive strand HBV DNA. The entecavir-TP K i for HBV DNA

polymerase is 0.0012 μM. Entecavir-TP is a weak inhibitor of cellular DNA polymerases α, β, and δ

with K i values of 18 to 40 µM. In addition, high exposures of entecavir had no relevant adverse effects

on γ polymerase or mitochondrial DNA synthesis in HepG2 cells (K i > 160 µM).

Antiviral activity: entecavir inhibited HBV DNA synthesis (50% reduction, EC 50 ) at a concentration

of 0.004 µM in human HepG2 cells transfected with wild-type HBV. The median EC 50 value for

entecavir against LVDr HBV (rtL180M and rtM204V) was 0.026 µM (range 0.010-0.059 µM).

8

Recombinant viruses encoding adefovir-resistant substitutions at either rtN236T or rtA181V remained

fully susceptible to entecavir.

An analysis of the inhibitory activity of entecavir against a panel of laboratory and clinical HIV-1

isolates using a variety of cells and assay conditions yielded EC 50 values ranging from 0.026 to

> 10 µM; the lower EC 50 values were observed when decreased levels of virus were used in the assay.

In cell culture, entecavir selected for an M184I substitution at micromolar concentrations, confirming

inhibitory pressure at high entecavir concentrations. HIV variants containing the M184V substitution

showed loss of susceptibility to entecavir (see section 4.4).

In HBV combination assays in cell culture, abacavir, didanosine, lamivudine, stavudine, tenofovir or

zidovudine were not antagonistic to the anti-HBV activity of entecavir over a wide range of

concentrations. In HIV antiviral assays, entecavir at micromolar concentrations was not antagonistic to

the anti-HIV activity in cell culture of these six NRTIs or emtricitabine.

Resistance in cell culture: relative to wild-type HBV, LVDr viruses containing rtM204V and

rtL180M substitutions within the reverse transcriptase exhibit 8-fold decreased susceptibility to

entecavir. Incorporation of additional ETVr amino acid changes rtT184, rtS202 or rtM250 decreases

entecavir susceptibility in cell culture. Substitutions observed in clinical isolates (rtT184A, C, F, G, I,

L, M or S; rtS202 C, G or I; and/or rtM250I, L or V) further decreased entecavir susceptibility 16- to

741-fold relative to wild-type virus. The ETVr substitutions at residues rtT184, rtS202 and rtM250

alone have only a modest effect on entecavir susceptibility, and have not been observed in the absence

of LVDr substitutions in more than 1000 patient samples sequenced. Resistance is mediated by

reduced inhibitor binding to the altered HBV reverse transcriptase, and resistant HBV exhibits reduced

replication capacity in cell culture.

Clinical experience: the demonstration of benefit is based on histological, virological, biochemical,

and serological responses after 48 weeks of treatment in active-controlled clinical trials of 1,633 adults

with chronic hepatitis B infection, evidence of viral replication and compensated liver disease. The

safety and efficacy of entecavir were also evaluated in an active-controlled clinical trial of

191 HBV-infected patients with decompensated liver disease and in a clinical trial of 68 patients

co-infected with HBV and HIV.

In studies in patients with compensated liver disease, histological improvement was defined as a

≥ 2-point decrease in Knodell necro-inflammatory score from baseline with no worsening of the

Knodell fibrosis score. Responses for patients with baseline Knodell Fibrosis Scores of 4 (cirrhosis)

were comparable to overall responses on all efficacy outcome measures (all patients had compensated

liver disease). High baseline Knodell necroinflammatory scores (> 10) were associated with greater

histological improvement in nucleoside-naive patients. Baseline ALT levels  2 times ULN and

baseline HBV DNA  9.0 log 10 copies/ml were both associated with higher rates of virologic response

(Week 48 HBV DNA < 400 copies/ml) in nucleoside-naive HBeAg-positive patients. Regardless of

baseline characteristics, the majority of patients showed histological and virological responses to

treatment.

9

Experience in nucleoside-naive patients with compensated liver disease:

Results at 48 weeks of randomised, double blind studies comparing entecavir (ETV) to lamivudine

(LVD) in HBeAg positive (022) and HBeAg negative (027) patients are presented in the table.

Nucleosi d e Naive

HBeAg Positive

(study 022)

HBeAg Negative

(study 027)

ETV

0.5 mg

once daily

LVD

100 mg

once daily

ETV

0.5 mg

once daily

LVD

100 mg

once daily

n

314 a

296 a

287 a

Histological improvement b

72%*

62%

70%*

61%

Ishak fibrosis score improvement

39%

35%

36%

38%

Ishak fibrosis score worsening

8%

10%

12%

15%

n

354

355

325

313

Viral load reduction (log 10 copies/ml) c

-6.86*

-5.39

-5.04*

-4.53

HBV DNA undetectable

(< 300 copies/ml by PCR) c

67%*

36%

90%*

72%

ALT normalisation (≤ 1 times ULN)

68%*

60%

78%*

71%

HBeAg Seroconversion

21%

18%

*p value vs lamivudine < 0.05

a patients with evaluable baseline histology (baseline Knodell Necroinflammatory Score  2)

b a primary endpoint

c Roche Cobas Amplicor PCR assay (LLOQ = 300 copies/ml)

Experience in lamivudine-refractory patients with compensated liver disease:

In a randomised, double-blind study in HBeAg positive lamivudine-refractory patients (026), with

85% of patients presenting LVDr mutations at baseline, patients receiving lamivudine at study entry

either switched to entecavir 1 mg once daily, with neither a washout nor an overlap period (n = 141),

or continued on lamivudine 100 mg once daily (n = 145). Results at 48 weeks are presented in the

table.

Lamivudine-refractory

HBeAg posi t ive (study 026)

ETV 1.0 mg once daily LVD 100 mg once daily

n

124 a

116 a

Histological improvement b

55%*

28%

Ishak fibrosis score improvement

34%*

16%

Ishak fibrosis score worsening

11%

26%

n

141

145

Viral load reduction (log 10 copies/ml) c

-5.11*

-0.48

HBV DNA undetectable (< 300 copies/ml

by PCR) c

19%*

1%

ALT normalisation (≤ 1 times ULN)

61%*

15%

HBeAg Seroconversion

8%

3%

*p value vs lamivudine < 0.05

a patients with evaluable baseline histology (baseline Knodell Necroinflammatory Score  2)

b a primary endpoint.

c Roche Cobas Amplicor PCR assay (LLOQ = 300 copies/ml)

Results beyond 48 weeks of treatment:

Treatment was discontinued when prespecified response criteria were met either at 48 weeks or during

the second year of treatment. Response criteria were HBV virological suppression (HBV DNA

< 0.7 MEq/ml by bDNA) and loss of HBeAg (in HBeAg positive patients) or ALT < 1.25 times ULN

10

(in HBeAg negative patients). Patients in response were followed for an additional 24 weeks off-

treatment. Patients who met virologic but not serologic or biochemical response criteria continued

blinded treatment. Patients who did not have a virologic response were offered alternative treatment.

Nucleoside-naive:

HBeAg positive (study 022): treatment with entecavir for up to 96 weeks (n = 354) resulted in

cumulative response rates of 80% for HBV DNA < 300 copies/ml by PCR, 87% for ALT

normalisation, 31% for HBeAg seroconversion and 2% for HBsAg seroconversion (5% for HBsAg

loss). For lamivudine (n = 355), cumulative response rates were 39% for HBV DNA < 300 copies/ml

by PCR, 79% for ALT normalisation, 26% for HBeAg seroconversion, and 2% for HBsAg

seroconversion (3% for HBsAg loss).

At end of dosing, among patients who continued treatment beyond 52 weeks (median of 96 weeks),

81% of 243 entecavir-treated and 39% of 164 lamivudine-treated patients had HBV DNA

< 300 copies/ml by PCR while ALT normalisation ( 1 times ULN) occurred in 79% of entecavir-

treated and 68% of lamivudine-treated patients.

HBeAg negative (study 027): treatment with entecavir up to 96 weeks (n = 325) resulted in cumulative

response rates of 94% for HBV DNA < 300 copies/ml by PCR and 89% for ALT normalisation versus

77% for HBV DNA < 300 copies/ml by PCR and 84% for ALT normalisation for lamivudine-treated

patients (n = 313).

For 26 entecavir-treated and 28 lamivudine-treated patients who continued treatment beyond 52 weeks

(median 96 weeks), 96% of entecavir-treated and 64% of lamivudine-treated patients had HBV DNA

< 300 copies/ml by PCR at end of dosing. ALT normalisation ( 1 times ULN) occurred in 27% of

entecavir-treated and 21% of lamivudine-treated patients at end of dosing.

For patients who met protocol-defined response criteria, response was sustained throughout the

24-week post-treatment follow-up in 75% (83/111) of entecavir responders vs 73% (68/93) for

lamivudine responders in study 022 and 46% (131/286) of entecavir responders vs 31% (79/253) for

lamivudine responders in study 027. By 48 weeks of post-treatment follow-up, a substantial number of

HBeAg negative patients lost response.

Liver biopsy results: 57 patients from the pivotal nucleoside-naive studies 022 (HBeAg positive) and

027 (HBeAg negative) who enrolled in a long-term rollover study were evaluated for long-term liver

histology outcomes. The entecavir dosage was 0.5 mg daily in the pivotal studies (mean exposure 85

weeks) and 1 mg daily in the rollover study (mean exposure 177 weeks), and 51 patients in the

rollover study initially also received lamivudine (median duration 29 weeks). Of these patients, 55/57

(96%) had histological improvement as previously defined (see above), and 50/57 (88%) had a

≥ 1-point decrease in Ishak fibrosis score. For patients with baseline Ishak fibrosis score ≥ 2, 25/43

(58%) had a ≥ 2-point decrease. All (10/10) patients with advanced fibrosis or cirrhosis at baseline

(Ishak fibrosis score of 4, 5 or 6) had a ≥ 1 point decrease (median decrease from baseline was

1.5 points). At the time of the long-term biopsy, all patients had HBV DNA < 300 copies/ml and 49/57

(86%) had serum ALT ≤ 1 times ULN. All 57 patients remained positive for HBsAg.

Lamivudine-refractory:

HBeAg positive (study 026): treatment with entecavir for up to 96 weeks (n = 141) resulted in

cumulative response rates of 30% for HBV DNA < 300 copies/ml by PCR, 85% for ALT

normalisation and 17% for HBeAg seroconversion.

For the 77 patients who continued entecavir treatment beyond 52 weeks (median 96 weeks), 40% of

patients had HBV DNA < 300 copies/ml by PCR and 81% had ALT normalisation ( 1 times ULN) at

end of dosing.

Age/gender:

There was no apparent difference in efficacy for entecavir based on gender (≈ 25% women in the

clinical trials) or age (≈ 5% of patients > 65 years of age).

11

Special populations

Patients with decompensated liver disease: in study 048, 191 patients with HBeAg positive or

negative chronic HBV infection and evidence of hepatic decompensation, defined as a CTP score of 7

or higher, received entecavir 1 mg once daily or adefovir dipivoxil 10 mg once daily. Patients were

either HBV-treatment-naïve or pretreated (excluding pretreatment with entecavir, adefovir dipivoxil,

or tenofovir disoproxil fumarate). At baseline, patients had a mean CTP score of 8.59 and 26% of

patients were CTP class C. The mean baseline Model for End Stage Liver Disease (MELD) score was

16.23. Mean serum HBV DNA by PCR was 7.83 log 10 copies/ml and mean serum ALT was 100 U/l;

54% of patients were HBeAg positive, and 35% of patients had LVDr substitutions at baseline.

Entecavir was superior to adefovir dipivoxil on the primary efficacy endpoint of mean change from

baseline in serum HBV DNA by PCR at week 24. Results for selected study endpoints at weeks 24

and 48 are shown in the table.

Week 24

Week 48

ETV

1 mg

once daily

Adefovir

Dipivoxil

10 mg

once daily

ETV

1 mg

once daily

Adefovir

Dipivoxil

10 mg

once daily

n

100

91

100

91

HBV DNA a

Proportion undetectable (<300 copies/ml) b

49%*

16%

57%*

20%

Mean change from baseline

(log 10 copies/ml) c

-4.48*

-3.40

-4.66

-3.90

Stable or improved CTP score b,d

66%

71%

61%

67%

MELD score

Mean change from baseline c,e

-2.0

-0.9

-2.6

-1.7

HBsAg loss b

1%

0

5%

0

Normalization of: f

ALT (≤1 X ULN) b

46/78 (59%)* 28/71 (39%) 49/78 (63%)* 33/71 (46%)

Albumin (≥1 X LLN) b

20/82 (24%) 14/69 (20%) 32/82 (39%) 20/69 (29%)

Bilirubin (≤1 X ULN) b

12/75 (16%) 10/65 (15%) 15/75 (20%) 18/65 (28%)

Prothrombin time (≤1 X ULN) b

9/95 (9%)

6/82 (7%)

8/95 (8%)

7/82 (9%)

a Roche COBAS Amplicor PCR assay (LLOQ = 300 copies/ml).

b NC=F (noncompleter=failure), meaning treatment discontinuations before the analysis week, including reasons such as

death, lack of efficacy, adverse event, noncompliance/loss-to-follow-up, are counted as failures (e.g., HBV

DNA ≥ 300 copies/ml)

c NC=M (noncompleters=missing)

d Defined as decrease or no change from baseline in CTP score.

e Baseline mean MELD score was 17.1 for ETV and 15.3 for adefovir dipivoxil.

f Denominator is patients with abnormal values at baseline.

*p<0.05

ULN=upper limit of normal, LLN=lower limit of normal.

The time to onset of HCC or death (whichever occurred first) was comparable in the two treatment

groups; on-study cumulative death rates were 23% (23/102) and 33% (29/89) for patients treated with

entecavir and adefovir dipivoxil, respectively, and on-study cumulative rates of HCC were 12%

(12/102) and 20% (18/89) for entecavir and adefovir dipivoxil, respectively .

For patients with LVDr substitutions at baseline, the percentage of patients with HBV DNA

<300 copies/ml was 44% for entecavir and 20% for adefovir at week 24 and 50% for entecavir and

17% for adefovir at week 48 .

12

HIV/HBV co-infected patients receiving concomitant HAART: study 038 included 67 HBeAg positive

and 1 HBeAg negative patients co-infected with HIV. Patients had stable controlled HIV (HIV RNA

< 400 copies/ml) with recurrence of HBV viraemia on a lamivudine-containing HAART regimen.

HAART regimens did not include emtricitabine or tenofovir disoproxil fumarate. At baseline

entecavir-treated patients had a median duration of prior lamivudine therapy of 4.8 years and median

CD4 count of 494 cells/mm 3 (with only 5 subjects having CD4 count < 200 cells/mm 3 ). Patients

continued their lamivudine-regimen and were assigned to add either entecavir 1 mg once daily

(n = 51) or placebo (n = 17) for 24 weeks followed by an additional 24 weeks where all received

entecavir. At 24 weeks the reduction in HBV viral load was significantly greater with entecavir (-3.65

vs an increase of 0.11 log 10 copies/ml). For patients originally assigned to entecavir treatment, the

reduction in HBV DNA at 48 weeks was -4.20 log 10 copies/ml, ALT normalisation had occurred in

37% of patients with abnormal baseline ALT and none achieved HBeAg seroconversion.

HIV/HBV co-infected patients not receiving concomitant HAART: entecavir has not been evaluated in

HIV/HBV co-infected patients not concurrently receiving effective HIV treatment. Reductions in HIV

RNA have been reported in HIV/HBV co-infected patients receiving entecavir monotherapy without

HAART. In some cases, selection of HIV variant M184V has been observed, which has implications

for the selection of HAART regimens that the patient may take in the future. Therefore, entecavir

should not be used in this setting due to the potential for development of HIV resistance (see section

4.4).

Paediatric population: the European Medicines Agency has deferred the obligation to submit the

results of studies with Baraclude in one or more subsets of the paediatric population with chronic

hepatitis B (see section 4.2 for information on paediatric use).

Clinical resistance: patients in clinical trials initially treated with entecavir 0.5 mg (nucleoside-naive)

or 1.0 mg (lamivudine-refractory) and with an on-therapy PCR HBV DNA measurement at or after

Week 24 were monitored for resistance.

Through Week 240 in nucleoside-naive studies, genotypic evidence of ETVr substitutions at rtT184,

rtS202, or rtM250 was identified in 3 patients treated with entecavir, 2 of whom experienced virologic

breakthrough (see table). These substitutions were observed only in the presence of LVDr

substitutions (rtM204V and rtL180M).

13

Emerging Genotypic Entecavir Resistance Through Year 5, Nucleoside-Naive Studies

Year 1

Year 2

Year 3 a Year 4 a

Year 5 a

Patients treated and monitored for

resistance b

663

278

149

121

108

Patients in specific year with:

- emerging genotypic ETVr c

1

0

- genotypic ETVr c with virologic

breakthrough d

1

0

1

0

Cumulative probability of:

0.2%

0.5%

1.2%

- emerging genotypic ETVr c

- genotypic ETVr c with virologic

breakthrough d

0.2%

0.8%

a Results reflect use of a 1-mg dose of entecavir for 147 of 149 patients in Year 3 and all patients in Years 4 and 5

and of combination entecavir-lamivudine therapy (followed by long-term entecavir therapy) for a median of 20

weeks for 130 of 149 patients in Year 3 and for 1 week for 1 of 121 patients in Year 4 in a rollover study.

b Includes patients with at least one on-therapy HBV DNA measurement by PCR at or after week 24 through week 58

(Year 1), after week 58 through week 102 (Year 2), after week 102 through week 156 (Year 3), after week 156

through week 204 (Year 4), or after week 204 through week 252 (Year 5).

c Patients also have LVDr substitutions.

d  1 log 10 increase above nadir in HBV DNA by PCR, confirmed with successive measurements or at the end of the

windowed time point.

ETVr substitutions (in addition to LVDr substitutions rtM204V/I ± rtL180M) were observed at

baseline in isolates from 10/187 (5%) lamivudine-refractory patients treated with entecavir and

monitored for resistance, indicating that prior lamivudine treatment can select these resistance

substitutions and that they can exist at a low frequency before entecavir treatment. Through Week 240,

3 of the 10 patients experienced virologic breakthrough (≥ 1 log 10 increase above nadir). Emerging

entecavir resistance in lamivudine-refractory studies through Week 240 is summarized in the table.

14

Genotypic Entecavir Resistance Through Year 5, Lamivudine-Refractory Studies

Year 1

Year 2

Year 3 a Year 4 a

Year 5 a

Patients treated and monitored for

resistance b

187

146

80

52

33

Patients in specific year with:

- emerging genotypic ETVr c

11

12

16

6

2

- genotypic ETVr c with virologic

breakthrough d

2 e

14 e

13 e

9 e

1 e

Cumulative probability of:

- emerging genotypic ETVr c

6.2%

15%

36.3%

46.6%

51.45%

- genotypic ETVr c with virologic

breakthrough d

1.1% e

10.7% e

27% e

41.3% e

43.6% e

a Results reflect use of combination entecavir-lamivudine therapy (followed by long-term entecavir therapy) for a

median of 13 weeks for 48 of 80 patients in Year 3, a median of 38 weeks for 10 of 52 patients in Year 4, and for 16

weeks for 1 of 33 patients in Year 5 in a rollover study.

b Includes patients with at least one on-therapy HBV DNA measurement by PCR at or after week 24 through week 58

(Year 1), after week 58 through week 102 (Year 2), after week 102 through week 156 (Year 3), after week 156 through

week 204 (Year 4), or after week 204 through week 252 (Year 5).

c Patients also have LVDr substitutions.

d  1 log 10 increase above nadir in HBV DNA by PCR, confirmed with successive measurements or at the end of the

windowed time point.

e ETVr occurring in any year; virologic breakthrough in specified year.

Among lamivudine-refractory patients with baseline HBV DNA < 10 7 log 10 copies/ml, 64% (9/14)

achieved HBV DNA < 300 copies/ml at Week 48. These 14 patients had a lower rate of genotypic

entecavir resistance (cumulative probability 18.8% through 5 years of follow-up) than the overall

study population (see table). Also, lamivudine-refractory patients who achieved HBV DNA < 10 4 log 10

copies/ml by PCR at Week 24 had a lower rate of resistance than those who did not (5-year cumulative

probability 17.6% [n= 50] versus 60.5% [n= 135], respectively).

5.2 Pharmacokinetic properties

Absorption: entecavir is rapidly absorbed with peak plasma concentrations occurring between

0.5-1.5 hours. The absolute bioavailability has not been determined. Based on urinary excretion of

unchanged drug, the bioavailability has been estimated to be at least 70%. There is a dose-

proportionate increase in C max and AUC values following multiple doses ranging from 0.1-1 mg.

Steady-state is achieved between 6-10 days after once daily dosing with  2 times accumulation. C max

and C min at steady-state are 4.2 and 0.3 ng/ml, respectively, for a dose of 0.5 mg, and 8.2 and

0.5 ng/ml, respectively, for 1 mg. The tablet and oral solution were bioequivalent in healthy subjects;

therefore, both forms may be used interchangeably.

Administration of 0.5 mg entecavir with a standard high-fat meal (945 kcal, 54.6 g fat) or a light meal

(379 kcal, 8.2 g fat) resulted in a minimal delay in absorption (1-1.5 hour fed vs. 0.75 hour fasted), a

decrease in C max of 44-46%, and a decrease in AUC of 18-20%. The lower C max and AUC when taken

with food is not considered to be of clinical relevance in nucleoside-naive patients but could affect

efficacy in lamivudine-refractory patients (see section 4.2).

Distribution: the estimated volume of distribution for entecavir is in excess of total body water.

Protein binding to human serum protein in vitro is  13%.

Biotransformation: entecavir is not a substrate, inhibitor or inducer of the CYP450 enzyme system.

Following administration of 14 C-entecavir, no oxidative or acetylated metabolites and minor amounts

of the phase II metabolites, glucuronide and sulfate conjugates, were observed.

15

Elimination: entecavir is predominantly eliminated by the kidney with urinary recovery of unchanged

drug at steady-state of about 75% of the dose. Renal clearance is independent of dose and ranges

between 360-471 ml/min suggesting that entecavir undergoes both glomerular filtration and net

tubular secretion. After reaching peak levels, entecavir plasma concentrations decreased in a

bi-exponential manner with a terminal elimination half-life of  128-149 hours. The observed drug

accumulation index is  2 times with once daily dosing, suggesting an effective accumulation half-life

of about 24 hours.

Hepatic impairment: pharmacokinetic parameters in patients with moderate or severe hepatic

impairment were similar to those in patients with normal hepatic function .

Renal impairment: entecavir clearance decreases with decreasing creatinine clearance. A 4 hour period

of haemodialysis removed  13% of the dose, and 0.3% was removed by CAPD. The

pharmacokinetics of entecavir following a single 1 mg dose in patients (without chronic hepatitis B

infection) are shown in the table below:

Baseline Creatinine Clearance (ml/min)

Unimpaired

> 80

Mild

> 50;

≤ 80

(n = 6)

Moderate

30-50

Severe

20-

< 30

(n = 6)

Severe

Managed with

Haemodialysis

(n = 6)

Severe

Managed

with CAPD

(n = 4)

(n = 6)

C max (ng/ml)

(CV%)

8.1

(30.7)

10.4

(37.2)

10.5

(22.7)

15.3

(33.8)

15.4

(56.4)

16.6

(29.7)

AUC (0-T)

(ng·h /ml)

(CV)

27.9

(25.6)

51.5

(22.8)

69.5

(22.7)

145.7

(31.5)

233.9

(28.4)

221.8

(11.6)

CLR (ml/min)

(SD)

383.2

(101.8)

197.9

(78.1)

135.6

(31.6)

40.3

(10.1)

NA

CLT/F (ml/min)

(SD)

588.1

(153.7)

309.2

(62.6)

226.3

(60.1)

100.6

(29.1)

50.6

(16.5)

35.7

(19.6)

Post-Liver transplant: entecavir exposure in HBV-infected liver transplant recipients on a stable dose

of cyclosporine A or tacrolimus (n = 9) was  2 times the exposure in healthy subjects with normal

renal function. Altered renal function contributed to the increase in entecavir exposure in these patients

(see section 4.4).

Gender: AUC was 14% higher in women than in men, due to differences in renal function and weight.

After adjusting for differences in creatinine clearance and body weight there was no difference in

exposure between male and female subjects.

Elderly: the effect of age on the pharmacokinetics of entecavir was evaluated comparing elderly

subjects in the age range 65-83 years (mean age females 69 years, males 74 years) with young subjects

in the age range 20-40 years (mean age females 29 years, males 25 years). AUC was 29% higher in

elderly than in young subjects, mainly due to differences in renal function and weight. After adjusting

for differences in creatinine clearance and body weight, elderly subjects had a 12.5% higher AUC than

young subjects.The population pharmacokinetic analysis covering patients in the age range

16-75 years did not identify age as significantly influencing entecavir pharmacokinetics.

Race: the population pharmacokinetic analysis did not identify race as significantly influencing

entecavir pharmacokinetics. However, conclusions can only be drawn for the Caucasian and Asian

groups as there were too few subjects in the other categories.

16

5.3 Preclinical safety data

In repeat-dose toxicology studies in dogs, reversible perivascular inflammation was observed in the

central nervous system, for which no-effect doses corresponded to exposures 19 and 10 times those in

humans (at 0.5 and 1 mg respectively). This finding was not observed in repeat-dose studies in other

species, including monkeys administered entecavir daily for 1 year at exposures ≥ 100 times those in

humans.

In reproductive toxicology studies in which animals were administered entecavir for up to 4 weeks, no

evidence of impaired fertility was seen in male or female rats at high exposures. Testicular changes

(seminiferous tubular degeneration) were evident in repeat-dose toxicology studies in rodents and dogs

at exposures ≥ 26 times those in humans. No testicular changes were evident in a 1-year study in

monkeys.

In pregnant rats and rabbits administered entecavir, no effect levels for embryotoxicity and maternal

toxicity corresponded to exposures ≥ 21 times those in humans. In rats, maternal toxicity, embryo-

foetal toxicity (resorptions), lower foetal body weights, tail and vertebral malformations, reduced

ossification (vertebrae, sternebrae, and phalanges), and extra lumbar vertebrae and ribs were observed

at high exposures. In rabbits, embryo-foetal toxicity (resorptions), reduced ossification (hyoid), and an

increased incidence of 13th rib were observed at high exposures. In a peri-postnatal study in rats, no

adverse effects on offspring were observed. In a separate study wherein entecavir was administered to

pregnant lactating rats at 10 mg/kg, both foetal exposure to entecavir and secretion of entecavir into

milk were demonstrated.

No evidence of genotoxicity was observed in an Ames microbial mutagenicity assay, a mammalian-

cell gene mutation assay, and a transformation assay with Syrian hamster embryo cells. A

micronucleus study and a DNA repair study in rats were also negative. Entecavir was clastogenic to

human lymphocyte cultures at concentrations substantially higher than those achieved clinically.

Two-year carcinogenicity studies: in male mice, increases in the incidences of lung tumours were

observed at exposures ≥ 4 and  2 times that in humans at 0.5 mg and 1 mg respectively. Tumour

development was preceded by pneumocyte proliferation in the lung which was not observed in rats,

dogs, or monkeys, indicating that a key event in lung tumour development observed in mice likely was

species-specific. Increased incidences of other tumours including brain gliomas in male and female

rats, liver carcinomas in male mice, benign vascular tumours in female mice, and liver adenomas and

carcinomas in female rats were seen only at high lifetime exposures. However, the no effect levels

could not be precisely established. The predictivity of the findings for humans is not known.

6.

PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core:

Crospovidone

Lactose monohydrate

Magnesium stearate

Cellulose, Microcrystalline

Povidone

Tablet coating:

Titanium dioxide

Hypromellose

Macrogol 400

Polysorbate 80 (E433)

17

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years

6.4 Special precautions for storage

Blisters:

Do not store above 30°C. Store in the original carton.

Bottles:

Do not store above 25°C. Keep the bottle tightly closed.

6.5 Nature and contents of container

Each carton contains either:

 30 x 1 film-coated tablets; 3 blister cards of 10 x 1 film-coated tablets each in Alu/Alu perforated

unit dose blisters, or

 90 x 1 film-coated tablets; 9 blister cards of 10 x 1 film-coated tablets each in Alu/Alu perforated

unit dose blisters.

High-density polyethylene (HDPE) bottle with child resistant polypropylene closure containing

30 film-coated tablets. Each carton contains one bottle.

Not all pack sizes and container types may be marketed.

6.6 Special precautions for disposal

No special requirements.

Any unused product or waste material should be disposed of in accordance with local requirements.

7.

MARKETING AUTHORISATION HOLDER

BRISTOL-MYERS SQUIBB PHARMA EEIG

Uxbridge Business Park

Sanderson Road

Uxbridge UB8 1DH

United Kingdom

8.

MARKETING AUTHORISATION NUMBER(S)

Blister packs:

EU/1/06/343/003

EU/1/06/343/006

Bottle packs:

EU/1/06/343/001

9.

DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

26 June 2006

18

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines

Agency http://www.ema.europa.eu/.

19

1.

NAME OF THE MEDICINAL PRODUCT

Baraclude 1 mg film-coated tablets

2.

QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 1 mg entecavir (as monohydrate).

Excipients: each tablet contains 241 mg lactose.

For a full list of excipients, see section 6.1.

3.

PHARMACEUTICAL FORM

Film-coated tablet (tablet)

Pink and triangular-shaped tablet with “BMS” debossed on one side and “1612” on the other.

4.

CLINICAL PARTICULARS

4.1 Therapeutic indications

Baraclude is indicated for the treatment of chronic hepatitis B virus (HBV) infection (see section 5.1)

in adults with:



compensated liver disease and evidence of active viral replication, persistently elevated serum

alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or

fibrosis.



decompensated liver disease (see section 4.4)

For both compensated and decompensated liver disease, this indication is based on clinical trial data in

nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to

patients with lamivudine-refractory hepatitis B, see sections 4.4 and 5.1.

4.2 Posology and method of administration

Therapy should be initiated by a physician experienced in the management of chronic hepatitis B

infection.

Baraclude should be taken orally, once-daily.

Compensated liver disease

Nucleoside naïve patients: the recommended dose is 0.5 mg once daily, with or without food.

Lamivudine-refractory patients (i.e. with evidence of viraemia while on lamivudine or the presence of

lamivudine resistance [LVDr] mutations) (see sections 4.4 and 5.1): the recommended dose is 1 mg

once daily, which must be taken on an empty stomach (more than 2 hours before or more than 2 hours

after a meal) (see section 5.2).

Decompensated liver disease

The recommended dose for patients with decompensated liver disease is 1 mg once daily, which must

be taken on an empty stomach (more than 2 hours before or more than 2 hours after a meal) (see

section 5.2). For patients with lamivudine-refractory hepatitis B, see sections 4.4 and 5.1.

20